Literature DB >> 18925907

2202 kidney transplant recipients with 10 years of graft function: what happens next?

A J Matas1, K J Gillingham, A Humar, R Kandaswamy, D E R Sutherland, W D Payne, T B Dunn, J S Najarian.   

Abstract

The ultimate goal of clinical transplantation is for the recipients to achieve long-term survival, with continuing graft function, that is equivalent to that of the age-matched general population. We studied subsequent outcome in kidney transplant recipients with 10 years of graft function. In all, 2202 kidney transplant recipients survived with graft function >10 years. For 10-year survivors, the actuarial 25-year patient survival rate for primary transplant living donor (LD) recipients was 57%; graft survival, 43%. For primary transplant deceased donor (DD) recipients, the actuarial 25-year patient survival rate was 39%; graft survival, 27%. The two major causes of late graft loss were death (with graft function) and chronic allograft nephropathy (tubular atrophy and interstitial fibrosis). The two major causes of death with function were cardiovascular disease (CVD) and malignancy. For nondiabetic recipients, the mean age at death with function from CVD was 54 +/- 13 years; for diabetic recipients, 53 +/- 7 years. By 20 years posttransplant, morbidity was common: >40% recipients had skin cancer (mean age for nondiabetic recipients, 53 +/- 13 years; for diabetics, 49 +/- 8 years), >10% had non-skin cancer (mean age for nondiabetic recipients, 53 +/- 16 years; for diabetics, 46 +/- 9 years), and >30% had CVD (mean age for nondiabetic recipients, 53 +/- 15 years; for diabetics, 47 +/- 9 years). We conclude that long-term transplant recipients have a high rate of morbidity and early mortality. As short-term results have improved, more focus is needed on long-term outcome.

Entities:  

Mesh:

Year:  2008        PMID: 18925907      PMCID: PMC2766174          DOI: 10.1111/j.1600-6143.2008.02414.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  25 in total

1.  Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors.

Authors:  K C Mange; M M Joffe; H I Feldman
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

2.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

Authors:  R A Wolfe; V B Ashby; E L Milford; A O Ojo; R E Ettenger; L Y Agodoa; P J Held; F K Port
Journal:  N Engl J Med       Date:  1999-12-02       Impact factor: 91.245

3.  Prednisone-free maintenance immunosuppression-a 5-year experience.

Authors:  Arthur J Matas; Raja Kandaswamy; Kristen J Gillingham; Lois McHugh; Hassan Ibrahim; Bertram Kasiske; Abhinav Humar
Journal:  Am J Transplant       Date:  2005-10       Impact factor: 8.086

4.  The UNOS Scientific Renal Transplant Registry--2000.

Authors:  J M Cecka
Journal:  Clin Transpl       Date:  2000

5.  The Banff 97 working classification of renal allograft pathology.

Authors:  L C Racusen; K Solez; R B Colvin; S M Bonsib; M C Castro; T Cavallo; B P Croker; A J Demetris; C B Drachenberg; A B Fogo; P Furness; L W Gaber; I W Gibson; D Glotz; J C Goldberg; J Grande; P F Halloran; H E Hansen; B Hartley; P J Hayry; C M Hill; E O Hoffman; L G Hunsicker; A S Lindblad; Y Yamaguchi
Journal:  Kidney Int       Date:  1999-02       Impact factor: 10.612

6.  Long-term outcome of pediatric renal transplantation: the Norwegian experience in three eras 1970-2006.

Authors:  Trine Tangeraas; Anna Bjerre; Bjorn Lien; Anders Kyte; Eirik Monn; Milada Cvancarova; Torbjørn Leivestad; Anna Varberg Reisaeter
Journal:  Pediatr Transplant       Date:  2008-01-14

7.  Risk factors for cardiovascular events after successful renal transplantation.

Authors:  Yves F C Vanrenterghem; Kathleen Claes; Giuseppe Montagnino; Steffen Fieuws; Bart Maes; Margarita Villa; Claudio Ponticelli
Journal:  Transplantation       Date:  2008-01-27       Impact factor: 4.939

Review 8.  Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.

Authors:  Stuart M Flechner; Jon Kobashigawa; Goran Klintmalm
Journal:  Clin Transplant       Date:  2008 Jan-Feb       Impact factor: 2.863

9.  Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.

Authors:  Osama A Gheith; Mohamed A Bakr; Mohamed A Fouda; Ahmed A Shokeir; Mohamed Sobh; Mohamed Ghoneim
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

10.  Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients.

Authors:  A C Webster; J C Craig; J M Simpson; M P Jones; J R Chapman
Journal:  Am J Transplant       Date:  2007-07-19       Impact factor: 8.086

View more
  33 in total

1.  Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation: A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals.

Authors:  Bénédicte Sautenet; Allison Tong; Karine E Manera; Jeremy R Chapman; Anthony N Warrens; David Rosenbloom; Germaine Wong; John Gill; Klemens Budde; Lionel Rostaing; Lorna Marson; Michelle A Josephson; Peter P Reese; Timothy L Pruett; Camilla S Hanson; Donal O'Donoghue; Helen Tam-Tham; Jean-Michel Halimi; Jenny I Shen; John Kanellis; John D Scandling; Kirsten Howard; Martin Howell; Nick Cross; Nicole Evangelidis; Philip Masson; Rainer Oberbauer; Samuel Fung; Shilpa Jesudason; Simon Knight; Sreedhar Mandayam; Stephen P McDonald; Steve Chadban; Tasleem Rajan; Jonathan C Craig
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

2.  Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops.

Authors:  Allison Tong; John Gill; Klemens Budde; Lorna Marson; Peter P Reese; David Rosenbloom; Lionel Rostaing; Germaine Wong; Michelle A Josephson; Timothy L Pruett; Anthony N Warrens; Jonathan C Craig; Benedicte Sautenet; Nicole Evangelidis; Angelique F Ralph; Camilla S Hanson; Jenny I Shen; Kirsten Howard; Klemens Meyer; Ronald D Perrone; Daniel E Weiner; Samuel Fung; Maggie K M Ma; Caren Rose; Jessica Ryan; Ling-Xin Chen; Martin Howell; Nicholas Larkins; Siah Kim; Sobhana Thangaraju; Angela Ju; Jeremy R Chapman
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

3.  The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation.

Authors:  Shelly Lichtenberg; Ruth Rahamimov; Hefziba Green; Benjamin D Fox; Eytan Mor; Uzi Gafter; Avry Chagnac; Benaya Rozen-Zvi
Journal:  Eur J Clin Pharmacol       Date:  2017-03-24       Impact factor: 2.953

4.  Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials.

Authors:  D Berglund; M Karlsson; A-R Biglarnia; T Lorant; G Tufveson; O Korsgren; B Carlsson
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

5.  [Modern immunosuppression after solid organ transplantation].

Authors:  J Beimler; C Morath; M Zeier
Journal:  Internist (Berl)       Date:  2014-02       Impact factor: 0.743

6.  Kidney transplantation in Romania: two transplant centers experience.

Authors:  A Gramaticu; D Siriopol; A Miron; D Tacu; I Sinescu; C Gingu; C Bucsa; A Nastasa; A Covic
Journal:  Int Urol Nephrol       Date:  2017-11-17       Impact factor: 2.370

7.  Multivessel coronary revascularization and outcomes in kidney transplant recipients.

Authors:  Colin R Lenihan; Maria E Montez-Rath; Wolfgang C Winkelmayer; Tara I Chang
Journal:  Transpl Int       Date:  2013-08-20       Impact factor: 3.782

8.  Antihypertensive Treatment in Kidney Transplant Recipients-A Current Single Center Experience.

Authors:  Ulrich Jehn; Katharina Schütte-Nütgen; Markus Strauss; Jan Kunert; Hermann Pavenstädt; Gerold Thölking; Barbara Suwelack; Stefan Reuter
Journal:  J Clin Med       Date:  2020-12-07       Impact factor: 4.241

9.  Orthogonal Comparison of Molecular Signatures of Kidney Transplants With Subclinical and Clinical Acute Rejection: Equivalent Performance Is Agnostic to Both Technology and Platform.

Authors:  S M Kurian; E Velazquez; R Thompson; T Whisenant; S Rose; N Riley; F Harrison; T Gelbart; J J Friedewald; J Charette; S Brietigam; J Peysakhovich; M R First; M M Abecassis; D R Salomon
Journal:  Am J Transplant       Date:  2017-04-03       Impact factor: 8.086

Review 10.  Role of TLRs and DAMPs in allograft inflammation and transplant outcomes.

Authors:  Faouzi Braza; Sophie Brouard; Steve Chadban; Daniel R Goldstein
Journal:  Nat Rev Nephrol       Date:  2016-03-30       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.